The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
Ask the Experts About

Choosing Your MedsChoosing Your Meds
Rollover images to visit our other forums!
Recent AnswersAsk a Question
  • Email Email
  • Glossary Glossary

New class coming soon.

Aug 15, 2006

Having been recently diagnosed and on HIV meds for the last 3 months (and doing great with Truvada/Lexiva/Norvir, btw), I was told that there is supposed to be a new drug class coming out in 2007. Do you know anything about this and when it is scheduled to be available?

Response from Dr. Young

Thanks for your post and for sharing your experiences.

There are two new drug classes on the near-term horizon.

The first is the CCR5 co-receptor inhibitors-- the one closest to approval is maraviroc (produced by Pfizer). This group of medications prevents HIV entry into the cell and blocks a human protein that's required for the HIV life cycle. Expanded access might be availabe by late 2006.

The second group (further back in development) are the HIV integrase inhibitors. There are two compounds in various stages of human study development, being developed by Merck and Gilead. I wouldn't expect an expanded access program for these for at least 6-12 months.

Thanks for reading. BY

OMG I think its time for meds.
lymph node swelling

  • Email Email
  • Glossary Glossary

 Get Email Notifications When This Forum Updates or Subscribe With RSS



This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint